Geschatte realtime
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
125,5 USD | +0,22% | -0,19% | +15,12% |
15:06 | MERCK & CO., INC. : BMO Capital handhaaft koopadvies | ZM |
14:06 | MERCK & CO., INC. : Leerink Partners ontvangt een koopadvies | ZM |
Vakgebied
- verkoop van farmaceutische producten (69,7%): voor de behandeling van hypertensie, osteoporose, atherosclerose, ademhalingsziekten, bacteriële en schimmelziekten, oogheelkundige en urologische ziekten, acute migraine, haaruitval bij mannen, enz;
- verkoop van vaccins (18%);
- verkoop van diergezondheidsproducten (9,4%);
- overige (2,9%).
De netto-omzet is als volgt geografisch verdeeld: Verenigde Staten (45,9%), Europa/Midden-Oosten/Afrika (24,5%), China (8,8%), Japan (6,1%), Azië/Pacific (6,1%), Latijns-Amerika (4,3%) en overige (4,3%).
Aantal werknemers: 71 000
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Pharmaceutical
89,1
%
| 52 005 | 87,7 % | 53 583 | 89,1 % | +3,03% |
Animal Health
9,4
%
| 5 550 | 9,4 % | 5 625 | 9,4 % | +1,35% |
Other
1,5
%
| 1 728 | 2,9 % | 907 | 1,5 % | -47,51% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
47,4
%
| 27 206 | 45,9 % | 28 480 | 47,4 % | +4,68% |
Europe, Middle East and Africa
22,0
%
| 14 493 | 24,4 % | 13 254 | 22,0 % | -8,55% |
China
11,3
%
| 5 191 | 8,8 % | 6 802 | 11,3 % | +31,03% |
Asia Pacific
5,4
%
| 3 614 | 6,1 % | 3 225 | 5,4 % | -10,76% |
Japan
5,3
%
| 3 629 | 6,1 % | 3 164 | 5,3 % | -12,81% |
Latin America
5,1
%
| 2 582 | 4,4 % | 3 086 | 5,1 % | +19,52% |
Other
3,5
%
| 2 568 | 4,3 % | 2 104 | 3,5 % | -18,07% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Robert Davis
CEO | Chief Executive Officer | 57 | 01-04-14 |
Director of Finance/CFO | 55 | 01-01-90 | |
Dave Williams
CTO | Chief Tech/Sci/R&D Officer | 55 | 01-08-20 |
Joseph Romanelli
IRC | Investor Relations Contact | 50 | 01-01-96 |
Peter Dannenbaum
IRC | Investor Relations Contact | - | 01-07-17 |
Andre Musto
PRN | Corporate Officer/Principal | - | 01-07-14 |
Brooke Hinkson
PRN | Corporate Officer/Principal | - | 01-08-15 |
Carol Bowden
PRN | Corporate Officer/Principal | - | 01-04-14 |
Dalton Smart
AUD | Comptroller/Controller/Auditor | 58 | 01-11-09 |
James Matteucci
PRN | Corporate Officer/Principal | - | 01-01-03 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Tom Glocer
BRD | Director/Board Member | 63 | 27-11-07 |
Pamela Craig
BRD | Director/Board Member | 67 | 01-09-15 |
Inge Thulin
BRD | Director/Board Member | 69 | 01-03-18 |
Patricia Russo
BRD | Director/Board Member | 71 | 01-09-95 |
Peter Wendell
BRD | Director/Board Member | 73 | 23-09-03 |
Director/Board Member | 69 | 26-05-20 | |
Robert Davis
CEO | Chief Executive Officer | 57 | 01-04-14 |
Douglas Baker
BRD | Director/Board Member | 65 | 24-05-22 |
Stephen Mayo
BRD | Director/Board Member | 62 | 15-03-21 |
Kathy Warden
BRD | Director/Board Member | 52 | 16-03-20 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 3 578 498 438 | 2 531 740 409 ( 70,75 %) | 1 045 470 249 ( 29,22 %) | 70,75 % |
Participaties
Naam | Aandelen | % | Totale waarde |
---|---|---|---|
13 443 693 | 10.62% | 266 247 500 $ | |
1 739 768 | 5.18% | 24 652 513 $ | |
XILIO THERAPEUTICS, INC. 5.39% | 1 483 414 | 5.39% | 1 602 087 $ |
EVAXION BIOTECH A/S 12.13% | 2 297 884 | 12.13% | 735 323 $ |
Bedrijfsgegevens
Bedrijven van de groep
Naam | Categorie en sector |
---|---|
Pharmaceuticals: Major
| |
Organon (India) Pvt Ltd.
Organon (India) Pvt Ltd. Pharmaceuticals: MajorHealth Technology Organon India Pvt Ltd. manufactures and distribution of pharmaceutical preparations. The company is headquartered in Mumbai, India. |
Pharmaceuticals: Major
|
Dashtag
Dashtag Financial ConglomeratesFinance Founded in 1906, Dashtag is a part of Organon & Co. and operates an investment holding British company. The private company is based in Hoddesdon, UK. |
Financial Conglomerates
|
MSD Sharp & Dohme GmbH
MSD Sharp & Dohme GmbH Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., MSD Sharp & Dohme GmbH develops and manufactures pharmaceutical products. The private company is based in Haar, Germany. The German company was founded in 1891. Chantal Friebertshäuser has been the CEO of the company since 2007. |
Pharmaceuticals: Major
|
Merck Holdings, Inc.
| |
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp. Pharmaceuticals: MajorHealth Technology Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ. |
Pharmaceuticals: Major
|
Intervet India Pvt Ltd.
| |
Essex Chemie AG
| |
Merck Sharp & Dohme Finance Europe Ltd.
Merck Sharp & Dohme Finance Europe Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 1993, Merck Sharp & Dohme Finance Europe Ltd. is a British company that provides business support services. Part of Merck & Co., Inc., the private company is based in Hoddesdon, UK. |
Miscellaneous Commercial Services
|
Sector
Verkoop per activiteit
Verkoop per regio
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+15,12% | 317 mld. | |
+25,15% | 672 mld. | |
+24,08% | 550 mld. | |
-6,34% | 351 mld. | |
+7,40% | 292 mld. | |
+3,26% | 211 mld. | |
+0,78% | 203 mld. | |
-10,32% | 144 mld. | |
-7,43% | 141 mld. | |
-3,20% | 113 mld. |